



Make Your Own Technology

An exciting, innovative delivery platform
for Antibodies and Therapeutic Proteins

September 13, 2023

Forward-looking statements

No representation, express or implied, is being given by RenBio, Inc. or its affiliates (individually and collectively, the “Company”) as to the accuracy or completeness of the information contained herein. The Company expressly disclaims any and all liability (whether known or unknown, asserted or unasserted, absolute or contingent, accrued or unaccrued, liquidated or unliquidated, due or become due, or otherwise) or any indemnification or other obligation which may be based on this presentation, errors therein or omissions therefrom.

This presentation is not and shall not be construed or viewed in any way to be a commitment, offer, obligation or agreement with respect to any transaction with the Company.

This presentation may contain “forward-looking” statements, which involve risks, uncertainties, and assumptions. All statements, other than statements of historical fact, should be deemed forward-looking statements, and reflect the current expectations and assumptions about future events and are not guarantees of future performance. Actual results could differ materially from the current expectations because of many factors. All forward-looking statements herein reflect opinions only as of the date of this presentation.

Copyright © RenBio, Inc. 2023. All rights reserved. Any further distribution or reproduction of this presentation, in whole or in part, is unauthorized.

Executive Summary

Potential paradigm shift in delivery of antibodies and therapeutic proteins for treatment of chronic diseases and prevention of infectious diseases.



Intramuscular electroporation of plasmid DNA enables durable, in vivo production of antibodies and therapeutic proteins

Company and financing overview

\$4M Series Seed

\$24M Series A

\$13M Nondilutive grants

Located in New York City

13 Employees

- ✓ Patent-protected platform technology
- ✓ Substantial commercial potential identified across a variety of indications
- ✓ Established clear proof of concept
- ✓ Able to support a wide variety of payloads
- ✓ Solves supply and distribution challenges associated with biologics
- ✓ Early clinical development funded by government agencies in Zika prevention



Rachel A. Liberatore, PhD
President & Chief Scientific Officer

BA in Molecular Biology from Princeton University, PhD in Cellular & Molecular Biology from Columbia University, 10+ years in scientific leadership and team management



Yaoxing Huang, PhD
Co-founder and Scientific Advisor
Associate Professor, Columbia University




David D. Ho, MD
Co-founder and Scientific Advisor

Professor, Columbia University & Director, Aaron Diamond AIDS Research Center | Scientific Founder, TaiMed Biologics (US FDA approved Trogarzo®) | Time Man of the Year

Our story

Considered, steady progress built on a solid foundation to advance the delivery of first-in-class and best-in-class DNA therapeutic technologies to humans



Our MYO Technology™ delivery platform enables an individual to make their own antibodies and therapeutic proteins



Bio Blueprints

Proprietary DNA plasmid encoding antibody or protein therapeutic



Delivery Device

Proprietary electroporation device



Antibody Factory

An individual's muscle cells, produce antibodies or therapeutic proteins following in vivo electroporation




Antibodies/Therapeutic Proteins

Circulate systemically following secretion by muscle cells


We continue to build the evidence to demonstrate the high value of our technology platform

In vivo animal data demonstrates promise for durable delivery of a payload within the therapeutic window

Traditional antibody protein delivery




MYO delivery of antibody genes



Targeting high value, high growth markets

The market for antibodies and therapeutic proteins is very large with wide utility.

Growing rapidly, the global market for antibodies was valued at \$210B in 2022, with an expected CAGR of 11.04% from 2023 to 2030.



There remain high levels of unmet need for the optimal development, supply, and use of antibodies and therapeutic proteins today

A faster, smoother, and cost-effective delivery platform would address many of these needs

Challenges that remain

Therapies with **short half-lives** require **frequent dosing** and ongoing monitoring, leading to inefficient clinic workflows and a risk of suboptimal efficacy and tolerability

Specialized production, purification and cold-chain requirements for transport and storage, drive long production lead times, complicate supply and distribution, and result in an unnecessarily **high COGs**



Meeting the need

Improving clinical utility for healthcare professionals by significantly reducing clinical workload with **easier, less frequent dosing**, negating the need for regular infusion clinics, reducing the burden of patient monitoring, and guaranteeing **real world efficacy** that meets that seen in clinical trials as patient adherence is no longer part of the equation

Reducing the COGs and ensuring flexible, fast product supply, distribution and storage by **simplifying manufacturing processes**, negating the need for specialized production facilities and removing any onerous **distribution and storage** criteria

Our MYO Technology™ has compelling advantages compared to other novel delivery platforms when applied to the management of systemic, chronic disease

<u>Feature</u>	MYO™ Technology	mRNA	AAV Gene Therapy
Durability	Months to years	Weeks to months	Years/Permanent
Redosable	****	***	*
Large genetic payload	****	***	**
Large scale manufacturing	****	**	*
Freedom from cold chain	****	*	*
Clinical safety of technology	***	***	*
Opportunity	Systemic activity Chronic disease Tx, Infectious disease Px	Localized activity Short half-life Vaccines	Specific tissue target Genetic disease Tx

Three pillars of opportunity identified for our MYO Technology™ platform

Multiple opportunities exist for realizing the full potential of drugs in large and rapidly growing markets

New molecule requiring long-term delivery

Antiviral antibodies and
other molecules for which
durability is critical

Life cycle management

Established brands wanting to
extend dominance


Differentiation in a competitive market

New/generic brands wanting
to make an impact in
crowded markets


MYO Technology™ has the potential for broad applicability

Compelling in vivo animal efficacy studies, using well accepted models, show applicability for diverse range of diseases from oncology to autoimmune


Arthritis




Breast Cancer



Influenza



Anemia




To demonstrate the clinical validity of our MYO Technology™ across infectious disease prevention and chronic disease treatment we have selected two diverse indications

Molecule applied to indication	Trial rationale	Current indication prevalence	Estimate of current market size	Potential market share with the delivery platform
Anti-Zika virus monoclonal antibody	Antiviral antibody for prevention of Zika virus infection in immunocompromised population and travelers trying to get pregnant	~2.7% of adults (US)	~90 K – 1.5 M patients (US)	HIGH: No vaccine or treatment currently exists
Granulocyte colony-stimulating factor (G-CSF) in Severe Chronic Neutropenia (SCN)	Therapeutic protein for treatment Rare disease Fastest path to MYO clinical validation Lowest barrier for clinical efficacy	~30 K patients (US)	~\$120 MM - \$460 MM (US)	HIGH: Assume targeting all patients taking G-CSF for SCN (current standard of care) Anticipated patient demand for therapies which are easier to use, driven by rare disease advocacy Potential for either branded or biosimilar payload Note potential competitor threat from emerging oral therapies considered limited as more appropriate for mild to moderate disease only


MYO Technology™ for Zika prevention and SCN treatment

Preclinical proof-of-concept established

Expression of a potent anti-Zika virus antibody




Sustained increase in neutrophil levels



Clinical proof-of-concept with a monoclonal antibody (Zika) and a therapeutic protein (G-CSF) will support expansion into multiple, high value markets

Phase 1 data with prototype molecules (anti-Zika monoclonal antibody and G-CSF) will demonstrate the potential for the MYO Technology platform



Many patients have benefited from the development of therapeutic antibodies and proteins

Our MYO Technology™ delivery platform has been designed to address the barriers limiting care today.

- ✓ Substantial commercial potential identified across a variety of indications
- ✓ Established clear proof of concept
- ✓ Able to support a wide variety of payloads
- ✓ Solves supply and distribution challenges
- ✓ Early clinical development funded by government agencies in Zika prevention



Non-confidential



Thank you

Help us to transform the lives of people globally
via the delivery of therapeutic antibodies and proteins
enabled by our MYO Technology™, easing and
expanding the use of these therapeutics.

